Q-omics provides the consensus-scored TMEM53 profile across patient tissues and cancer cell-line models. TMEM53 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, TMEM53 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TMEM53 RNA expression shows 17,103 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, KIRC, and ACC as cancer lineages where TMEM53 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM53 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM53 survival associations across molecular data types. TMEM53 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM53 RNA expression–survival associations across cancer types. High TMEM53 expression shows unfavorable associations in LGG, LUSC, UCS, KIRC and ESCA, but favorable associations in UVM. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for TMEM53 RNA expression.
This table summarizes TMEM53 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM53. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM53 shows lower tumor expression in KIRC, KICH, LUSC and KIRP and higher tumor expression in BLCA and THCA. The KIRC box plot shows higher TMEM53 RNA expression in normal versus tumor tissue (log2 FC = −0.785, t-test p < 0.001).
This table shows molecular features associated with TMEM53 in patient tissues and cancer cell lines. In patient samples, TMEM53 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM53 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
